Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Acepromazine
- Accession Number
- DB01614
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.
- Structure
Structure for DB01614 (Acepromazine)
- Synonyms
- 1-[10-(3-DIMETHYLAMINO-propyl)-10H-phenothiazin-2-yl]-ethanone
- 10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone
- 10-(3-dimethylaminopropyl)phenothiazine-3-ethylone
- Acetazine
- Acetopromazine
- Acetylpromazine
- Product Ingredients
Ingredient UNII CAS InChI Key Acepromazine maleate 37862HP2OM 3598-37-6 FQRHOOHLUYHMGG-BTJKTKAUSA-N - International/Other Brands
- Acezine 2 / Atravet
- Categories
- Alpha1 Antagonists
- Antipsychotic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Dopamine Agents
- Dopamine Antagonists
- Nervous System
- Neurotransmitter Agents
- Phenothiazines
- Phenothiazines With Aliphatic Side-Chain
- Psycholeptics
- Psychotropic Drugs
- Sulfur Compounds
- Tranquilizing Agents
- UNII
- 54EJ303F0R
- CAS number
- 61-00-7
- Weight
- Average: 326.456
Monoisotopic: 326.145284026 - Chemical Formula
- C19H22N2OS
- InChI Key
- NOSIYYJFMPDDSA-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3
- IUPAC Name
- 1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one
- SMILES
- CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O
Pharmacology
- Indication
Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.
- Structured Indications
- Not Available
- Pharmacodynamics
Acepromazine is one of the phenothiazine derivative psychotropic drugs. Acepromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Acepromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
- Mechanism of action
Acepromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
Target Actions Organism AD(2) dopamine receptor antagonistHuman AD(1A) dopamine receptor antagonistHuman A5-hydroxytryptamine receptor 2A antagonistHuman A5-hydroxytryptamine receptor 1A antagonistHuman UAlpha-1A adrenergic receptor antagonistHuman UAlpha-1B adrenergic receptor antagonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
3 hours in horses.
- Clearance
- Not Available
- Toxicity
Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine Acepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Acepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Methylenedioxyamphetamine Acepromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Acepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 5'-Deoxy-5'-Methylthioadenosine The serum concentration of Acepromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine. Experimental 7-Nitroindazole The risk or severity of adverse effects can be increased when Acepromazine is combined with 7-Nitroindazole. Experimental Acebutolol Acepromazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceprometazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Acepromazine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Acepromazine is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Acepromazine is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Acepromazine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Acepromazine. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Acepromazine is combined with Allopregnanolone. Investigational Almasilate Almasilate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Acepromazine. Approved, Investigational Aloglutamol Aloglutamol can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Acepromazine. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Acepromazine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Acepromazine. Approved, Illicit, Investigational Alprenolol Acepromazine may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Aluminium Aluminium can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Amisulpride Acepromazine may increase the antipsychotic activities of Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Acepromazine. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Acepromazine. Approved, Illicit Amodiaquine The serum concentration of Acepromazine can be increased when it is combined with Amodiaquine. Approved, Investigational Amoxapine The risk or severity of adverse effects can be increased when Acepromazine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Acepromazine is combined with Amperozide. Experimental Amphetamine Acepromazine may decrease the stimulatory activities of Amphetamine. Approved, Illicit, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acepromazine. Approved, Investigational Arotinolol Acepromazine may increase the hypotensive activities of Arotinolol. Investigational Artemether The serum concentration of Acepromazine can be increased when it is combined with Artemether. Approved Artemisinin The serum concentration of Acepromazine can be increased when it is combined with Artemisinin. Investigational Artemotil The serum concentration of Acepromazine can be increased when it is combined with Artemotil. Approved Artenimol The serum concentration of Acepromazine can be increased when it is combined with Artenimol. Approved, Investigational Artesunate The serum concentration of Acepromazine can be increased when it is combined with Artesunate. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Acepromazine. Approved Atenolol Acepromazine may increase the hypotensive activities of Atenolol. Approved Atovaquone The serum concentration of Acepromazine can be increased when it is combined with Atovaquone. Approved Azaperone The risk or severity of adverse effects can be increased when Acepromazine is combined with Azaperone. Investigational, Vet Approved Azelastine Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Acepromazine. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine. Illicit Befunolol Acepromazine may increase the hypotensive activities of Befunolol. Experimental Benperidol The risk or severity of adverse effects can be increased when Acepromazine is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Acepromazine. Approved, Investigational Benzphetamine Acepromazine may decrease the stimulatory activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Acepromazine is combined with Benzyl alcohol. Approved Betaxolol Acepromazine may increase the hypotensive activities of Betaxolol. Approved, Investigational Bevantolol Acepromazine may increase the hypotensive activities of Bevantolol. Approved Bezitramide Acepromazine may increase the hypotensive activities of Bezitramide. Experimental, Illicit, Withdrawn Bismuth Subcitrate Bismuth Subcitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Bisoprolol Acepromazine may increase the hypotensive activities of Bisoprolol. Approved Bopindolol Acepromazine may increase the hypotensive activities of Bopindolol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Acepromazine. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Acepromazine is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Acepromazine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Acepromazine. Approved Brotizolam The risk or severity of adverse effects can be increased when Acepromazine is combined with Brotizolam. Approved, Investigational, Withdrawn Bucindolol Acepromazine may increase the hypotensive activities of Bucindolol. Investigational Bufuralol Acepromazine may increase the hypotensive activities of Bufuralol. Experimental, Investigational Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine. Approved, Investigational Bupranolol Acepromazine may increase the hypotensive activities of Bupranolol. Approved Buprenorphine Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Acepromazine. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Acepromazine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Acepromazine. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Acepromazine. Approved, Illicit, Vet Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Acepromazine. Approved Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium silicate Calcium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Canertinib The risk or severity of adverse effects can be increased when Acepromazine is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Acepromazine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Acepromazine. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Acepromazine. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Acepromazine. Approved Carteolol Acepromazine may increase the hypotensive activities of Carteolol. Approved Carvedilol Acepromazine may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Acepromazine may increase the hypotensive activities of Celiprolol. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Acepromazine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Acepromazine. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acepromazine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Acepromazine. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Acepromazine. Approved Chloroquine The serum concentration of Acepromazine can be increased when it is combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acepromazine. Approved Chlorphentermine Acepromazine may decrease the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorproguanil The serum concentration of Acepromazine can be increased when it is combined with Chlorproguanil. Investigational Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acepromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Acepromazine. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Acepromazine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Acepromazine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Acepromazine. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Acepromazine. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Acepromazine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Acepromazine is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Acepromazine. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Acepromazine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Acepromazine is combined with Clopenthixol. Experimental Cloranolol Acepromazine may increase the hypotensive activities of Cloranolol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Acepromazine is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Acepromazine. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Acepromazine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Acepromazine. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Acepromazine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine. Approved Cycloguanil embonate The serum concentration of Acepromazine can be increased when it is combined with Cycloguanil embonate. Experimental Cyclopropane The risk or severity of adverse effects can be increased when Acepromazine is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Acepromazine. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Acepromazine. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Acepromazine. Approved Dapoxetine The risk or severity of adverse effects can be increased when Acepromazine is combined with Dapoxetine. Investigational Dapsone The serum concentration of Acepromazine can be increased when it is combined with Dapsone. Approved, Investigational Deramciclane The risk or severity of adverse effects can be increased when Acepromazine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Acepromazine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Acepromazine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Acepromazine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acepromazine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acepromazine. Approved, Vet Approved Dextroamphetamine Acepromazine may decrease the stimulatory activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acepromazine. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Acepromazine. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acepromazine. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Acepromazine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Acepromazine. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Acepromazine is combined with Diethyl ether. Experimental Diethylpropion Acepromazine may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Acepromazine. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine. Approved, Illicit Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acepromazine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acepromazine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acepromazine. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acepromazine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acepromazine. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Acepromazine is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Acepromazine. Approved, Investigational Doxycycline The serum concentration of Acepromazine can be increased when it is combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Acepromazine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Acepromazine. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Acepromazine is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Acepromazine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Acepromazine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Acepromazine. Approved, Investigational Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Acepromazine. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Acepromazine is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Acepromazine. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Acepromazine. Approved, Investigational Epanolol Acepromazine may increase the hypotensive activities of Epanolol. Experimental Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Acepromazine. Approved Escitalopram The risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram. Approved, Investigational Esmolol Acepromazine may increase the hypotensive activities of Esmolol. Approved Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Acepromazine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Acepromazine. Approved, Investigational Ethanol Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Acepromazine. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Acepromazine. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Acepromazine. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acepromazine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Acepromazine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Acepromazine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine. Approved Etoperidone The risk or severity of adverse effects can be increased when Acepromazine is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Acepromazine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Acepromazine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Acepromazine. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Acepromazine. Approved, Illicit, Withdrawn Fenfluramine The risk or severity of adverse effects can be increased when Acepromazine is combined with Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Acepromazine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Acepromazine. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Acepromazine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Acepromazine. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Acepromazine. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Acepromazine. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Acepromazine. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Acepromazine is combined with Fospropofol. Approved, Illicit, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Acepromazine. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Acepromazine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Acepromazine. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Acepromazine. Approved, Illicit, Investigational Gepefrine Acepromazine may decrease the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Acepromazine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Acepromazine. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Acepromazine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Acepromazine. Approved, Illicit, Withdrawn Halofantrine The serum concentration of Acepromazine can be increased when it is combined with Halofantrine. Approved Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Acepromazine. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Acepromazine. Approved Hydrocodone Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine. Approved, Illicit Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Hydroxyamphetamine Acepromazine may decrease the stimulatory activities of Hydroxyamphetamine. Approved Hydroxychloroquine The serum concentration of Acepromazine can be increased when it is combined with Hydroxychloroquine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Acepromazine. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Acepromazine. Approved Indalpine The risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine. Investigational, Withdrawn Indenolol Acepromazine may increase the hypotensive activities of Indenolol. Withdrawn Indiplon The risk or severity of adverse effects can be increased when Acepromazine is combined with Indiplon. Investigational Iofetamine I-123 Acepromazine may decrease the stimulatory activities of Iofetamine I-123. Approved Isocarboxazid The therapeutic efficacy of Acepromazine can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Acepromazine. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ketazolam is combined with Acepromazine. Approved Ketobemidone The risk or severity of adverse effects can be increased when Acepromazine is combined with Ketobemidone. Approved, Investigational Labetalol Acepromazine may increase the hypotensive activities of Labetalol. Approved Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Acepromazine. Approved, Investigational Landiolol Acepromazine may increase the hypotensive activities of Landiolol. Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Acepromazine. Approved, Investigational Levobunolol Acepromazine may increase the hypotensive activities of Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Acepromazine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Acepromazine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Acepromazine. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Acepromazine. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acepromazine. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Acepromazine. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine. Approved, Vet Approved Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Acepromazine. Approved, Investigational Lisdexamfetamine Acepromazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Lithium Lithium may increase the neurotoxic activities of Acepromazine. Approved Lofentanil The risk or severity of adverse effects can be increased when Acepromazine is combined with Lofentanil. Illicit Loprazolam The risk or severity of adverse effects can be increased when Acepromazine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Acepromazine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Acepromazine. Approved Lorcaserin The risk or severity of adverse effects can be increased when Lorcaserin is combined with Acepromazine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Acepromazine is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine. Approved Lumefantrine The serum concentration of Acepromazine can be increased when it is combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Acepromazine. Approved, Investigational Magaldrate Magaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate The therapeutic efficacy of Acepromazine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Acepromazine. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Acepromazine is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Acepromazine. Approved Medazepam The risk or severity of adverse effects can be increased when Acepromazine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Medetomidine. Vet Approved Mefloquine The serum concentration of Acepromazine can be increased when it is combined with Mefloquine. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Acepromazine. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Acepromazine is combined with Melperone. Approved, Investigational Mephedrone Acepromazine may decrease the stimulatory activities of Mephedrone. Investigational Mephentermine Acepromazine may decrease the stimulatory activities of Mephentermine. Approved Mepindolol Acepromazine may increase the hypotensive activities of Mepindolol. Experimental Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Acepromazine is combined with Meptazinol. Experimental Mequitazine Acepromazine may increase the arrhythmogenic activities of Mequitazine. Approved Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Acepromazine. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Acepromazine. Approved, Illicit Methamphetamine Acepromazine may decrease the stimulatory activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Acepromazine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Acepromazine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Acepromazine. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Acepromazine. Approved Methotrimeprazine Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Acepromazine. Approved, Investigational, Vet Approved Methoxyphenamine Acepromazine may decrease the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Acepromazine. Approved Methylecgonine The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylecgonine. Experimental Methylphenidate The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Acepromazine. Approved Metipranolol Acepromazine may increase the hypotensive activities of Metipranolol. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine. Approved, Investigational Metoprolol Acepromazine may increase the hypotensive activities of Metoprolol. Approved, Investigational Metyrosine Acepromazine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine. Approved, Illicit Midomafetamine Acepromazine may decrease the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Milnacipran The risk or severity of adverse effects can be increased when Acepromazine is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Investigational Mirtazapine Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mizoribine The serum concentration of Acepromazine can be increased when it is combined with Mizoribine. Investigational MMDA Acepromazine may decrease the stimulatory activities of MMDA. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Acepromazine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved, Investigational Nadolol Acepromazine may increase the hypotensive activities of Nadolol. Approved Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Acepromazine. Approved Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Acepromazine. Approved, Investigational Nebivolol Acepromazine may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Acepromazine is combined with Nefazodone. Approved, Withdrawn Nicomorphine Acepromazine may increase the hypotensive activities of Nicomorphine. Experimental Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Acepromazine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Acepromazine. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Acepromazine is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Acepromazine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Acepromazine. Approved Olanzapine The risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Acepromazine. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Acepromazine. Approved Opium The risk or severity of adverse effects can be increased when Acepromazine is combined with Opium. Approved, Illicit Orphenadrine Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Acepromazine. Approved Oxethazaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Acepromazine. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Acepromazine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Acepromazine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Acepromazine. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Acepromazine. Approved Paraldehyde Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine. Approved, Investigational Penbutolol Acepromazine may increase the hypotensive activities of Penbutolol. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Acepromazine is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Acepromazine. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved Perazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Acepromazine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Acepromazine. Approved Phenazocine The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine. Approved Phenibut The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Acepromazine. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenoxyethanol. Approved Phentermine Acepromazine may decrease the stimulatory activities of Phentermine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Acepromazine. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Acepromazine. Approved Pindolol Acepromazine may increase the hypotensive activities of Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Acepromazine is combined with Pipamperone. Approved, Investigational Piperaquine The serum concentration of Acepromazine can be increased when it is combined with Piperaquine. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Acepromazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Acepromazine is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Acepromazine. Approved Platelet Activating Factor Acepromazine may increase the hypotensive activities of Platelet Activating Factor. Experimental Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Acepromazine. Approved Practolol Acepromazine may increase the hypotensive activities of Practolol. Approved Pramipexole Acepromazine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine. Approved, Illicit Pregabalin The therapeutic efficacy of Acepromazine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Acepromazine. Approved Primaquine The serum concentration of Acepromazine can be increased when it is combined with Primaquine. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Acepromazine. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Acepromazine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Acepromazine. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine. Approved, Vet Approved Proguanil The serum concentration of Acepromazine can be increased when it is combined with Proguanil. Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Acepromazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Acepromazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Acepromazine is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Acepromazine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Propoxycaine. Approved Propranolol Acepromazine may increase the hypotensive activities of Propranolol. Approved, Investigational Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Acepromazine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Acepromazine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Acepromazine is combined with PSD502. Investigational Pseudoephedrine Acepromazine may decrease the stimulatory activities of Pseudoephedrine. Approved Pyrimethamine The serum concentration of Acepromazine can be increased when it is combined with Pyrimethamine. Approved, Investigational, Vet Approved Pyronaridine The serum concentration of Acepromazine can be increased when it is combined with Pyronaridine. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Acepromazine. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Acepromazine. Approved Quinacrine The serum concentration of Acepromazine can be increased when it is combined with Quinacrine. Approved, Investigational Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Acepromazine. Approved, Investigational Quinidine The serum concentration of Acepromazine can be increased when it is combined with Quinidine. Approved, Investigational Quinine The serum concentration of Acepromazine can be increased when it is combined with Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Acepromazine is combined with Raclopride. Investigational Radicicol The serum concentration of Acepromazine can be increased when it is combined with Radicicol. Experimental Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Acepromazine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Acepromazine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Acepromazine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Acepromazine is combined with Ritanserin. Investigational Ritobegron Acepromazine may decrease the stimulatory activities of Ritobegron. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Acepromazine. Approved Romifidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Romifidine. Vet Approved Ropinirole Acepromazine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine. Approved Rotigotine Acepromazine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Acepromazine. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Acepromazine. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Acepromazine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Acepromazine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Acepromazine is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine. Approved, Vet Approved Sinefungin The serum concentration of Acepromazine can be increased when it is combined with Sinefungin. Experimental Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved Sotalol Acepromazine may increase the hypotensive activities of Sotalol. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Acepromazine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine. Approved, Investigational Sulfadoxine The serum concentration of Acepromazine can be increased when it is combined with Sulfadoxine. Approved, Investigational Sulfametopyrazine The serum concentration of Acepromazine can be increased when it is combined with Sulfametopyrazine. Approved, Withdrawn Sulpiride Acepromazine may increase the antipsychotic activities of Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Acepromazine is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Acepromazine. Approved, Investigational Suvorexant Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tafenoquine The serum concentration of Acepromazine can be increased when it is combined with Tafenoquine. Investigational Talinolol Acepromazine may increase the hypotensive activities of Talinolol. Investigational Tandospirone The risk or severity of adverse effects can be increased when Acepromazine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Acepromazine. Approved, Investigational Tedizolid Phosphate The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Acepromazine. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Acepromazine. Approved, Investigational Tertatolol Acepromazine may increase the hypotensive activities of Tertatolol. Experimental Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acepromazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Acepromazine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrodotoxin. Investigational Thalidomide Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Acepromazine is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Acepromazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Acepromazine. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Acepromazine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Tilidine. Experimental Timolol Acepromazine may increase the hypotensive activities of Timolol. Approved Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Acepromazine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Acepromazine. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Acepromazine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Acepromazine is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Acepromazine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Acepromazine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Acepromazine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Acepromazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Acepromazine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine. Approved, Vet Approved Trimethoprim The serum concentration of Acepromazine can be increased when it is combined with Trimethoprim. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Acepromazine. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Acepromazine. Approved Tromethamine Tromethamine can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Acepromazine. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Acepromazine. Approved Venlafaxine The risk or severity of adverse effects can be increased when Acepromazine is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Acepromazine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Acepromazine. Approved Vilazodone The risk or severity of adverse effects can be increased when Acepromazine is combined with Vilazodone. Approved Vinyl ether The risk or severity of adverse effects can be increased when Acepromazine is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Acepromazine is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Acepromazine is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Acepromazine. Approved Zimelidine The risk or severity of adverse effects can be increased when Acepromazine is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Acepromazine. Approved Zolazepam The risk or severity of adverse effects can be increased when Acepromazine is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acepromazine. Approved, Investigational Zolpidem Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Acepromazine. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Acepromazine. Approved Zotepine The risk or severity of adverse effects can be increased when Acepromazine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Acepromazine. Approved, Investigational - Food Interactions
- Avoid alcohol
- Take with food to reduce irritation
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015552
- KEGG Drug
- D02604
- PubChem Compound
- 6077
- PubChem Substance
- 46508205
- ChemSpider
- 5852
- BindingDB
- 50131719
- ChEBI
- 44932
- ChEMBL
- CHEMBL39560
- PharmGKB
- PA164783999
- HET
- PMZ
- Wikipedia
- Acepromazine
- ATC Codes
- N05AA04 — Acepromazine
- PDB Entries
- 1lvj
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) < 25 °C PhysProp boiling point (°C) 230 °C at 5.00E-01 mm Hg PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0098 mg/mL ALOGPS logP 4.32 ALOGPS logP 3.49 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 16.06 ChemAxon pKa (Strongest Basic) 8.5 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 23.55 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 99.35 m3·mol-1 ChemAxon Polarizability 37.17 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9852 Blood Brain Barrier + 0.9844 Caco-2 permeable + 0.8203 P-glycoprotein substrate Substrate 0.8092 P-glycoprotein inhibitor I Inhibitor 0.8563 P-glycoprotein inhibitor II Inhibitor 0.857 Renal organic cation transporter Inhibitor 0.7087 CYP450 2C9 substrate Non-substrate 0.7438 CYP450 2D6 substrate Substrate 0.8618 CYP450 3A4 substrate Substrate 0.6468 CYP450 1A2 substrate Inhibitor 0.9106 CYP450 2C9 inhibitor Non-inhibitor 0.9319 CYP450 2D6 inhibitor Inhibitor 0.9115 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.9105 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7333 Ames test Non AMES toxic 0.849 Carcinogenicity Non-carcinogens 0.9292 Biodegradation Not ready biodegradable 0.9829 Rat acute toxicity 2.7963 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9537 hERG inhibition (predictor II) Inhibitor 0.7813
Spectra
- Mass Spec (NIST)
- Download (7.84 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiazines
- Sub Class
- Phenothiazines
- Direct Parent
- Phenothiazines
- Alternative Parents
- Alkyldiarylamines / Diarylthioethers / Acetophenones / Aryl alkyl ketones / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Phenothiazine / Alkyldiarylamine / Diarylthioether / Acetophenone / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- phenothiazines, tertiary amino compound, methyl ketone, aromatic ketone (CHEBI:44932)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
- Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
- Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- DRD1
- Uniprot ID
- P21728
- Uniprot Name
- D(1A) dopamine receptor
- Molecular Weight
- 49292.765 Da
References
- Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
References
- Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
- Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134]
- Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
- Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
- Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
Drug created on August 29, 2007 14:12 / Updated on March 02, 2018 05:22